

PRESS RELEASE

WISE's Breakthrough Medical Devices Receive Approval for Commercialization in Australia

Milan, 31 August 2023. - Leading the change in neuromonitoring, WISE Srl has reached another significant milestone in its journey. The company is elated to announce that its groundbreaking WISE Cortical Strip has received approval for commercialization in Australia. This approval marks the WISE Cortical Strip's association with ARTG #413731, further expanding its global footprint.

Widely recognized for its revolutionary Supersonic Technology enabling highly ergonomic and conformable medical electrodes, WISE continues its mission of transforming the landscape of intraoperative and implantable electrodes for neuromonitoring, neuromodulation, and brain-machine interfacing (BMI). The WISE Cortical Strip, a part of the WISEneuro® Monitoring product family, stands out as an innovative single-use medical device designed explicitly for Intraoperative Neurophysiological Monitoring (IONM).

With a unique design, the WISE Cortical Strip employs stretchable platinum contacts enveloped in a soft, thin silicone film. This pioneering approach ensures ergonomic and seamlessly conform to the brain surface. Standing in stark contrast to conventional cortical electrodes that use rigid metal discs, the WISE Cortical Strip promotes unique softness, thinness, and stability on the brain's surface, heralding a new era in brain monitoring technology.

The WISE Cortical Strip's innovation is not just in its design; the efficacy of the WISE Cortical Strip has been validated through a successful multicentric pre-market clinical study in Europe (NCT03731455). This rigorous study demonstrated the product's safety, superior performance in terms of electrical impedance under physiological conditions, and exceptional usability. These results have been published in the journal *Clinical Neurophysiology* (<https://doi.org/10.1016/j.clinph.2022.07.497>).

Luca Ravagnan, CEO of WISE, commented on this achievement, "This approval in Australia is a further demonstration of our commitment to elevating patient care worldwide. By making our products available in new markets, we're ensuring that more healthcare professionals have the tools they need to offer superior patient care."

Australia's commercialization approval paves the way for WISE to introduce its state-of-the-art brain monitoring technology to a broader audience, reaffirming its position as a trailblazer in the medical device sector.

For more information, please visit: www.wiseneuro.com

For media inquiries or additional information regarding this announcement, please contact:

WISE Srl

Dr. Luca Ravagnan, CEO

T: +39 3337657189

E: info@wiseneuro.com

About WISE:

WISE Srl is at the forefront of developing a truly innovative generation of electrodes for neuromonitoring, neuromodulation, and brain-machine interfacing, driven by its proprietary Supersonic Technology.

In the domains of neuromonitoring and neuromodulation, electrodes and leads must be surgically implanted on neural tissues such as the brain and spinal cord to either apply electrical stimuli or record electrical activity. Leveraging WISE's Supersonic Technology, the company manufactures electrodes consisting of stretchable electronic circuits integrated into ultra-thin elastomeric foils. As a result, WISE's electrodes possess exceptional ergonomics, conformability, softness, and thinness, facilitating superior adhesion, minimal invasiveness, and optimal adaptability to neural tissues.

Beyond neuromonitoring, WISE is actively involved in neuromodulation and is currently developing its revolutionary WISEneuro® Modulation product family. The flagship product in this lineup is the Heron® lead, a groundbreaking expandable percutaneous paddle lead specifically designed for Spinal Cord Stimulation (SCS). Pain therapists and neurosurgeons will be able for the first time to implant percutaneously a directional and anatomic conforming SCS leads, marking a significant advancement in patient care.

WISE was founded by a team of material scientists from the University of Milan, and it received initial funding from prominent entities such as Agite!, Atlante Seed, Atlante Ventures, b-to-v, HTGF, Xyence Capital, New Frontier, and private investors. Moreover, in 2020, the company successfully closed a Series C funding round with new investors including CDP Venture Capital SGR, Indaco Ventures I Fund, and EUREKA! Venture SGR. Since 2016, WISE has established its production facility in Cologno Monzese, Milan, Italy, and maintains an office in Berlin, Germany.

For more information about WISE and its pioneering advancements in neurotechnology, please visit: www.wiseneuro.com.